TB-500

TB-500 is a synthetic version of the naturally occurring 43-amino acid peptide Thymosin Beta-4 (TB4), focusing on the active region responsible for actin binding and cell motility. Its primary mechanism involves binding to and sequestering monomeric actin (G-actin), which plays a central role in cellular migration, proliferation, and differentiation.

By modulating the actin cytoskeleton, TB-500 enables cells to move more efficiently to sites of injury. This enhanced cell migration is particularly relevant in wound healing, where keratinocytes, endothelial cells, and fibroblasts must travel to damaged tissue. TB-500 also promotes angiogenesis — new blood vessel formation — by upregulating VEGF and other angiogenic factors.

Beyond structural repair, TB-500 exhibits potent anti-inflammatory properties, reducing the production of pro-inflammatory cytokines while promoting the expression of anti-inflammatory mediators. Research also suggests it can reduce fibrosis (scar tissue formation) and promote functional tissue regeneration rather than mere scarring, which is critical for outcomes in cardiac, muscular, and dermal repair.

Thymosin Beta-4 was first isolated from the thymus gland in the 1960s by Allan Goldstein and colleagues. Initially studied for its role in immune regulation, researchers later discovered its profound effects on wound healing and tissue repair. The synthetic fragment TB-500 was developed to capture the most bioactive region of the full protein.

Research expanded significantly in the 2000s, with studies demonstrating TB-500's ability to promote cardiac repair following myocardial infarction, accelerate dermal wound healing, and reduce inflammation in various animal models. Its role in equine medicine, where it has been used extensively in racehorses for soft tissue repair, brought it to wider attention in the sports science community.